Cancer is one of the most dreaded diseases, though with early detection, some forms of cancer could have better chances of remission. Even with early detection, however, different forms of cancer could require different forms of treatment.
Researchers at the Sylvester Comprehensive Cancer Center at the Miami Miller School of Medicine have recently concluded that a receptor for advanced glycation end-products (RAGE) could be targeted in order to decrease tumor growth in breast cancer. This could also decrease metastasis of the cancer to the lung and liver.
Blocking RAGE might be the key to reducing tumor growth and metastasis. Professor Barry I. Hudson, author of the study and one of the cancer researchers and assistant Professor of Medicine at Miller School, said that in the study they have done multiple approaches in targeting RAGE.
Once RAGE is activated it then changes cellular properties. This then starts tumor activity with increased cell migration and invasion, according to Science Daily. By targeting RAGE, it might then be possible to treat other forms of cancer and not just breast cancer, as Professor Hudson has observed.
Eureka Alert notes that by blocking RAGE, tumor growth has been reduced and metastasis has been slowed down. Dr. Judy Salermo, CEO of Susan G. Komen said that the study is a big step in understanding more about breast cancer. Susan G. Komen has provided a career catalyst research grant to Professor Hudson on his research about RAGE and how to block it.
Research continues on RAGE and how to successfully block it. The research could be instrumental in not only helping the fight against breast cancer, but even other forms of cancer. Professor Hudson notes that the research has shown that blocking RAGE could be a viable approach towards cancer treatment.
iTechPost also reports of a new chemical-free sterilizer to control Zika mosquitoes.
